HIV/hepatitis C co-infection and hepatic fibrosis: looking beyond HIV-associated immune suppression; the contribution of hepatic steatosis and insulin resistance

被引：3
|
作者：
Bhagani, Sanjay [1 ]
机构：
[1] Royal Free Hosp, Dept Infect Dis & HIV Med, London NW3 2QG, England
来源：
GUT | 2009年 / 58卷 / 12期
关键词：
INFECTED PATIENTS; HCV GENOTYPE; RISK-FACTORS; VIRUS; STEATOHEPATITIS; PROGRESSION; DISEASE; IMPACT;
D O I：
10.1136/gut.2009.184473
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1579 / 1581
页数：5
相关论文
共 50 条
  • [31] Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection - The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index
    Rollet-Kurhajec, Kathleen C.
    Moodie, Erica E. M.
    Walmsley, Sharon
    Cooper, Curtis
    Pick, Neora
    Klein, Marina B.
    PLOS ONE, 2015, 10 (06):
  • [32] HIV entry and replication stellate cells promotes cellular activation and fibrogenesis: Implications for hepatic fibrosis in HIV/HCV co-infection
    Tuyama, Ana C.
    Hong, Feng
    Schecter, Alison D.
    Mosoian, Arevik
    Chen, Benjamin K.
    Chen, Ping
    Klotman, Mary E.
    Bansal, Meena B.
    HEPATOLOGY, 2007, 46 (04) : 291A - 291A
  • [33] A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection
    Moqueet, Nasheed
    Kanagaratham, Cynthia
    Gill, M. John
    Hull, Mark
    Walmsley, Sharon
    Radzioch, Danuta
    Saeed, Sahar
    Platt, Robert W.
    Klein, Marina B.
    PLOS ONE, 2017, 12 (05):
  • [34] EFFECTS OF ACE-INHIBITORS ON LIVER FIBROSIS IN HIV AND HEPATITIS C (HCV) CO-INFECTION
    Reese, Lindsey
    Tider, Diane
    Stivala, Alicia
    Fishbein, Dawn A.
    HEPATOLOGY, 2008, 48 (04) : 1160A - 1161A
  • [35] Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus
    Marks, KM
    Petrovic, LM
    Talal, AH
    Murray, MP
    Gulick, RM
    Glesby, MJ
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (11): : 1943 - 1949
  • [36] Quantification of hepatic FOXP3+ T-lymphocytes in HIV/hepatitis C co-infection - a mechanism for poor outcomes?
    Williams, S.
    Donaldson, E.
    Van der Kleij, T.
    Dixon, L.
    Fisher, M.
    Tibble, J.
    Gilleece, Y.
    Klenerman, P.
    Banham, A.
    Howard, M.
    Webster, D.
    HIV MEDICINE, 2013, 14 : 4 - 4
  • [37] Cannabinoids and reduced risk of hepatic steatosis in HIV-HCV co-infection: paving the way for future clinical research
    Marcellin, Fabienne
    Fontaine, Helene
    Serfaty, Lawrence
    Sogni, Philippe
    Carrieri, Maria Patrizia
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (05) : 377 - 380
  • [38] Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis
    Shalimar
    Rout, G.
    Gupta, S.
    Gunjan, D.
    Kedia, S.
    Nayak, B.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S535 - S535
  • [39] Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients
    Pal, Ananya
    Panigrahi, Rajesh
    Biswas, Avik
    Datta, Sibnarayan
    Sarkar, Neelakshi
    Guha, Subhashish Kamal
    Saha, Bibhuti
    Banerjee, Arup
    Chakrabarti, Sekhar
    Chakravarty, Runu
    VIROLOGY, 2013, 436 (01) : 134 - 142
  • [40] EFFECT OF HIV ON LEVELS OF SERUM MARKERS OF LIVER INFLAMMATION AND FIBROSIS IN HEPATITIS C VIRUS CO-INFECTION
    Nunez, Marina
    Beltz, Abbie
    High, Kevin
    HEPATOLOGY, 2009, 50 (04) : 923A - 924A
12345